,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3891 Ranchero Drive,Suite 150,Ann Arbor,MI,48108,United States,734 887 3903,https://www.esperion.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",199,"{'maxAge': 1, 'name': 'Mr. Sheldon L. Koenig', 'age': 56, 'title': 'Pres, CEO & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 1197433, 'exercisedValue': 0, 'unexercisedValue': 137453}",3,5,9,8,7,1693526400,1672444800,86400,4,1.38,1.38,1.37,1.43,1.38,1.38,1.37,1.43,0.0,0.129668,10.142857,3668273,3668273,3090093,3412210,3412210,1.38,1.42,3000,4000,151931472,1.12,8.87,1.7282026,1.5196,3.1539,0.0,0.0,USD,532084096,-2.5281599,86079029,106994000,15179133,13408792,1690761600,1693440000,0.1419,0.0050999997,0.85753,4.04,0.1732,-3.688,1672444800,1703980800,1688083200,-222258000,-2.81,0.14,-0.04,1:6,1370908800,6.052,-3.14,NGM,EQUITY,ESPR,ESPR,"Esperion Therapeutics, Inc.","Esperion Therapeutics, Inc.",1372253400,America/New_York,EDT,-14400000,1.42,22.0,2.0,10.28,9.0,1.9,buy,9,138470000,1.294,-169470000,522902016,1.673,2.166,87913000,1.068,-0.39407003,-70419000,-130880128,-164411008,0.369,-0.64663005,-1.9277,-1.93144,USD,
1,3891 Ranchero Drive,Suite 150,Ann Arbor,MI,48108,United States,734 887 3903,https://www.esperion.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",199,"{'maxAge': 1, 'name': 'Mr. Benjamin O. Looker', 'age': 40, 'title': 'Gen. Counsel', 'yearBorn': 1982, 'fiscalYear': 2022, 'totalPay': 550350, 'exercisedValue': 0, 'unexercisedValue': 0}",3,5,9,8,7,1693526400,1672444800,86400,4,1.38,1.38,1.37,1.43,1.38,1.38,1.37,1.43,0.0,0.129668,10.142857,3668273,3668273,3090093,3412210,3412210,1.38,1.42,3000,4000,151931472,1.12,8.87,1.7282026,1.5196,3.1539,0.0,0.0,USD,532084096,-2.5281599,86079029,106994000,15179133,13408792,1690761600,1693440000,0.1419,0.0050999997,0.85753,4.04,0.1732,-3.688,1672444800,1703980800,1688083200,-222258000,-2.81,0.14,-0.04,1:6,1370908800,6.052,-3.14,NGM,EQUITY,ESPR,ESPR,"Esperion Therapeutics, Inc.","Esperion Therapeutics, Inc.",1372253400,America/New_York,EDT,-14400000,1.42,22.0,2.0,10.28,9.0,1.9,buy,9,138470000,1.294,-169470000,522902016,1.673,2.166,87913000,1.068,-0.39407003,-70419000,-130880128,-164411008,0.369,-0.64663005,-1.9277,-1.93144,USD,
2,3891 Ranchero Drive,Suite 150,Ann Arbor,MI,48108,United States,734 887 3903,https://www.esperion.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",199,"{'maxAge': 1, 'name': 'Dr. JoAnne Micale Foody FACC, M.D.', 'age': 56, 'title': 'Chief Medical Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 771191, 'exercisedValue': 0, 'unexercisedValue': 0}",3,5,9,8,7,1693526400,1672444800,86400,4,1.38,1.38,1.37,1.43,1.38,1.38,1.37,1.43,0.0,0.129668,10.142857,3668273,3668273,3090093,3412210,3412210,1.38,1.42,3000,4000,151931472,1.12,8.87,1.7282026,1.5196,3.1539,0.0,0.0,USD,532084096,-2.5281599,86079029,106994000,15179133,13408792,1690761600,1693440000,0.1419,0.0050999997,0.85753,4.04,0.1732,-3.688,1672444800,1703980800,1688083200,-222258000,-2.81,0.14,-0.04,1:6,1370908800,6.052,-3.14,NGM,EQUITY,ESPR,ESPR,"Esperion Therapeutics, Inc.","Esperion Therapeutics, Inc.",1372253400,America/New_York,EDT,-14400000,1.42,22.0,2.0,10.28,9.0,1.9,buy,9,138470000,1.294,-169470000,522902016,1.673,2.166,87913000,1.068,-0.39407003,-70419000,-130880128,-164411008,0.369,-0.64663005,-1.9277,-1.93144,USD,
3,3891 Ranchero Drive,Suite 150,Ann Arbor,MI,48108,United States,734 887 3903,https://www.esperion.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",199,"{'maxAge': 1, 'name': 'Mr. Benjamin  Halladay M.B.A.', 'age': 36, 'title': 'Chief Financial Officer', 'yearBorn': 1986, 'exercisedValue': 0, 'unexercisedValue': 0}",3,5,9,8,7,1693526400,1672444800,86400,4,1.38,1.38,1.37,1.43,1.38,1.38,1.37,1.43,0.0,0.129668,10.142857,3668273,3668273,3090093,3412210,3412210,1.38,1.42,3000,4000,151931472,1.12,8.87,1.7282026,1.5196,3.1539,0.0,0.0,USD,532084096,-2.5281599,86079029,106994000,15179133,13408792,1690761600,1693440000,0.1419,0.0050999997,0.85753,4.04,0.1732,-3.688,1672444800,1703980800,1688083200,-222258000,-2.81,0.14,-0.04,1:6,1370908800,6.052,-3.14,NGM,EQUITY,ESPR,ESPR,"Esperion Therapeutics, Inc.","Esperion Therapeutics, Inc.",1372253400,America/New_York,EDT,-14400000,1.42,22.0,2.0,10.28,9.0,1.9,buy,9,138470000,1.294,-169470000,522902016,1.673,2.166,87913000,1.068,-0.39407003,-70419000,-130880128,-164411008,0.369,-0.64663005,-1.9277,-1.93144,USD,
4,3891 Ranchero Drive,Suite 150,Ann Arbor,MI,48108,United States,734 887 3903,https://www.esperion.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",199,"{'maxAge': 1, 'name': 'Mr. Glenn P. Brame', 'age': 64, 'title': 'Chief Technical Operations Officer', 'yearBorn': 1958, 'exercisedValue': 0, 'unexercisedValue': 0}",3,5,9,8,7,1693526400,1672444800,86400,4,1.38,1.38,1.37,1.43,1.38,1.38,1.37,1.43,0.0,0.129668,10.142857,3668273,3668273,3090093,3412210,3412210,1.38,1.42,3000,4000,151931472,1.12,8.87,1.7282026,1.5196,3.1539,0.0,0.0,USD,532084096,-2.5281599,86079029,106994000,15179133,13408792,1690761600,1693440000,0.1419,0.0050999997,0.85753,4.04,0.1732,-3.688,1672444800,1703980800,1688083200,-222258000,-2.81,0.14,-0.04,1:6,1370908800,6.052,-3.14,NGM,EQUITY,ESPR,ESPR,"Esperion Therapeutics, Inc.","Esperion Therapeutics, Inc.",1372253400,America/New_York,EDT,-14400000,1.42,22.0,2.0,10.28,9.0,1.9,buy,9,138470000,1.294,-169470000,522902016,1.673,2.166,87913000,1.068,-0.39407003,-70419000,-130880128,-164411008,0.369,-0.64663005,-1.9277,-1.93144,USD,
5,3891 Ranchero Drive,Suite 150,Ann Arbor,MI,48108,United States,734 887 3903,https://www.esperion.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",199,"{'maxAge': 1, 'name': 'Tiffany  Aldrich M.B.A.', 'title': 'Associate Director of Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",3,5,9,8,7,1693526400,1672444800,86400,4,1.38,1.38,1.37,1.43,1.38,1.38,1.37,1.43,0.0,0.129668,10.142857,3668273,3668273,3090093,3412210,3412210,1.38,1.42,3000,4000,151931472,1.12,8.87,1.7282026,1.5196,3.1539,0.0,0.0,USD,532084096,-2.5281599,86079029,106994000,15179133,13408792,1690761600,1693440000,0.1419,0.0050999997,0.85753,4.04,0.1732,-3.688,1672444800,1703980800,1688083200,-222258000,-2.81,0.14,-0.04,1:6,1370908800,6.052,-3.14,NGM,EQUITY,ESPR,ESPR,"Esperion Therapeutics, Inc.","Esperion Therapeutics, Inc.",1372253400,America/New_York,EDT,-14400000,1.42,22.0,2.0,10.28,9.0,1.9,buy,9,138470000,1.294,-169470000,522902016,1.673,2.166,87913000,1.068,-0.39407003,-70419000,-130880128,-164411008,0.369,-0.64663005,-1.9277,-1.93144,USD,
6,3891 Ranchero Drive,Suite 150,Ann Arbor,MI,48108,United States,734 887 3903,https://www.esperion.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",199,"{'maxAge': 1, 'name': 'Ms. Betty Jean Swartz', 'title': 'Chief Strategy Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",3,5,9,8,7,1693526400,1672444800,86400,4,1.38,1.38,1.37,1.43,1.38,1.38,1.37,1.43,0.0,0.129668,10.142857,3668273,3668273,3090093,3412210,3412210,1.38,1.42,3000,4000,151931472,1.12,8.87,1.7282026,1.5196,3.1539,0.0,0.0,USD,532084096,-2.5281599,86079029,106994000,15179133,13408792,1690761600,1693440000,0.1419,0.0050999997,0.85753,4.04,0.1732,-3.688,1672444800,1703980800,1688083200,-222258000,-2.81,0.14,-0.04,1:6,1370908800,6.052,-3.14,NGM,EQUITY,ESPR,ESPR,"Esperion Therapeutics, Inc.","Esperion Therapeutics, Inc.",1372253400,America/New_York,EDT,-14400000,1.42,22.0,2.0,10.28,9.0,1.9,buy,9,138470000,1.294,-169470000,522902016,1.673,2.166,87913000,1.068,-0.39407003,-70419000,-130880128,-164411008,0.369,-0.64663005,-1.9277,-1.93144,USD,
7,3891 Ranchero Drive,Suite 150,Ann Arbor,MI,48108,United States,734 887 3903,https://www.esperion.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.",199,"{'maxAge': 1, 'name': 'Mr. Eric J. Warren R.Ph.', 'age': 50, 'title': 'Chief Commercial Officer', 'yearBorn': 1972, 'exercisedValue': 0, 'unexercisedValue': 0}",3,5,9,8,7,1693526400,1672444800,86400,4,1.38,1.38,1.37,1.43,1.38,1.38,1.37,1.43,0.0,0.129668,10.142857,3668273,3668273,3090093,3412210,3412210,1.38,1.42,3000,4000,151931472,1.12,8.87,1.7282026,1.5196,3.1539,0.0,0.0,USD,532084096,-2.5281599,86079029,106994000,15179133,13408792,1690761600,1693440000,0.1419,0.0050999997,0.85753,4.04,0.1732,-3.688,1672444800,1703980800,1688083200,-222258000,-2.81,0.14,-0.04,1:6,1370908800,6.052,-3.14,NGM,EQUITY,ESPR,ESPR,"Esperion Therapeutics, Inc.","Esperion Therapeutics, Inc.",1372253400,America/New_York,EDT,-14400000,1.42,22.0,2.0,10.28,9.0,1.9,buy,9,138470000,1.294,-169470000,522902016,1.673,2.166,87913000,1.068,-0.39407003,-70419000,-130880128,-164411008,0.369,-0.64663005,-1.9277,-1.93144,USD,
